Northwest Biotherapeutics, of Bethesda, a biotechnology company, has raised $35 million in financing, the company announced. The funds come from a $25 million equity investment by British-based C.F. Woodford Equity Income Fund and a $10 million mortgage on the company’s ...

Tagged with: Northwest Biotherapeutics Inc.

Northwest Biotherapeutics, of Bethesda, a biotechnology company developing non-toxic personalized immune therapies for solid tumor cancers, announced that it has been added to the MSCI Global MicroCap Index.

Tagged with: maryland Northwest Biotherapeutics Inc.

BETHESDA — Drug developer Northwest Biotherapeutics Inc. said Thursday it sold $10 million worth of its stock to a health care institutional investor that it did not identify. Northwest Biotherapeutics said the private placement valued its shares at $3.90 each, ...

Tagged with: biotechnology Business Northwest Biotherapeutics Inc. Stocks

Northwest Biotherapeutics Inc., of Bethesda, a development-stage biotechnology company focused on developing therapies to improve the body’s immune response to cancer, reported a net loss of $67.3 million, or 5.72 per share, in the 12 months ended Dec. 31, 2012, compared to a loss of $32.8 million, or $5.58 per share, for the same period in 2011.

Tagged with: biotechnology Business earnings Northwest Biotherapeutics Inc.

Northwest Biotherapeutics Inc., of Bethesda, a biotechnology company developing personalized immune therapies for solid tumor cancers, announced that it has been issued a U.S. patent covering novel processes for manufacturing human dendritic cells.

Tagged with: bethesda biotech maryland Northwest Biotherapeutics Inc. patent Technology